In an international, randomized, phase III clinical trial, researchers added an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) to standard endocrine therapy for women with advanced HR-positive/HER2-negative breast cancer.
The researchers report that adding the CDK inhibitor significantly increased survival among the women, compared with using the endocrine therapy alone.
After a follow-up period of 42 months, the survival rate among women who received the new inhibitor was 70%, compared with just 46% among women who only received the endocrine therapy.
